| Entries |
| Document | Title | Date |
|---|
| 20080263689 | Methods for Identifying Modulators of Protein Kinase C-Epsilon (Pkce) and Method of Treatment of Aberrant Glucose Metabolism Associated Therewith - The present invention provides novel cell-based and animal-based assays for determining antagonists of PKCε and uses of the isolated antagonist compounds for modulating insulin clearance and secretion. The invention also provides novel animals and cells such as animals and cells suitable for use in the assays. | 10-23-2008 |
| 20080295191 | METHOD FOR PRODUCING CLONED DOG | 11-27-2008 |
| 20090019560 | CLONED RAT BY NUCLEAR TRANSFER USING ENUCLEATED RAT OOCYTES - The invention relates to a method for cloning in the rat by nuclear transfer. The invention further relates to the rats obtained thus, in the foetal or adult state, as well as use thereof for the production of molecules of interest or as study models. | 01-15-2009 |
| 20090025097 | SHRNA AND SIRNA AND MIRNA EXPRESSION IN A LIVING ORGANISM UNDER CONTROL OF A CODON-OPTIMIZED REPRESSOR GENE - The present invention relates to a biological entity, notably a rat, carrying a regulator construct comprising a specific repressor gene and a responder construct comprising at least one segment corresponding to a short hairpin RNA (shRNA) or corresponding to complementary short interfering RNA (siRNA) strands or corresponding to miRNA, said at least one segment being under control of a promoter which contains an operator sequence corresponding to the repressor. The invention further relates to a method for preparing said biological entity and its use. | 01-22-2009 |
| 20090094709 | Use of protein phosphatase 2Ce (PP2Ce) having dephosphorylating action on AMPK - A drug includes, RNA interference with protein phosphatase 2Cε (PP2Cε) as an active ingredient. According to the present invention, the activation and deactivation of AMPK can be regulated. | 04-09-2009 |
| 20090106852 | Influenza Therapeutic - The present invention provides methods and compositions for inhibiting influenza infection and/or replication based on the phenomenon of RNA interference (RNAi) well as systems for identifying effective siRNAs and shRNAs for inhibiting influenza virus and systems for studying influenza virus infective mechanisms. The invention also provides methods and compositions for inhibiting infection, pathogenicity and/or replication of other infectious agents, particularly those that infect cells that are directly accessible from outside the body, e.g., skin cells or mucosal cells. In addition, the invention provides compositions comprising an RNAi-inducing entity, e.g., an siRNA, shRNA, or RNAi-inducing vector targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for treatment of influenza. | 04-23-2009 |
| 20090113563 | Probe for detecting nuclear receptor agonist or antagonist and method for screening agonist or antagonist to nuclear receptor with the use of the same - A probe for detecting an agonist or an antagonist to a nuclear receptor, in which, at least, a ligand-recognition site containing a ligand-binding domain of the nuclear receptor is connected with a binding-responsive site containing a peptide chain that specifically binds to a coactivator-binding site in the ligand-binding domain by a flexible linker to construct a fusion structure [ligand-recognition site/linker/binding-responsive site], and two reporters are connected with the respective ends of the fusion structure. | 04-30-2009 |
| 20090133136 | Inducible SIRNA expression cassette and method of use - An inducible siRNA expression polynucleotide and methods for its use are provided. The expression polynucleotide comprises a bicistronic expression cassette that encodes a repressor and a detectable marker, wherein the repressor controls expression of siRNA expression in the absence of an inducer. | 05-21-2009 |
| 20090138978 | Use of bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes - The present invention is directed to the use of Bridge-1 polynucleotides and Bridge-1 polypeptides, as well as activators and inhibitors of Bridge-1 activity, in the treatment of Bridge-1 mediated disorders, including diabetes. | 05-28-2009 |
| 20090178152 | Use of the Ornithine Transcarbamylase (OTC), as a Marker for Diagnosing Brain Damages - The present invention pertains to the domain of brain diseases, and provides novel markers and methods for diagnosing a brain alteration in an individual, especially in patients suffering from neurodegenerative diseases such as Alzheimer's disease. The present invention also provides tools for evaluating the probability, for an individual, of developing the disease, as well as a target for identifying new drugs for treating neurodegenerative diseases such as Alzheimer's disease. In particular, the invention provides a genetic marker based on combination of two single nucleotide polymorphism, at positions −389 and −241 of the ornithine transcarbamylase (OTC) gene. | 07-09-2009 |
| 20090193531 | Methods and compositions for RNA Interference - The present invention provides methods for attenuating gene expression in a cell using gene-targeted double stranded RNA (dsRNA). The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited (the “target” gene). | 07-30-2009 |
| 20090205061 | Taste Receptors Of The T1R Family From Domestic Cat - The present invention relates to the discovery of several genes of the domestic cat ( | 08-13-2009 |
| 20090217400 | Enzymes, cells and methods for site specific recombination at asymmetric sites - The present invention relates to enzymes, compositions and methods for catalyzing asymmetric recombination of non-palindromic recombination sites in a cell free system, in isolated cells or in living organisms. The enzymes and methods of the invention are suitable for mediating specific recombinations between DNA sequences comprising specific recombination sites without being limited to strict palindromic symmetry within each recombination site. | 08-27-2009 |
| 20090255003 | Diagnostic and therapeutic target SLC39A11 proteins for neurodegenerative diseases - The present invention discloses a dysregulation of the SLC39A11 gene and the protein products thereof in Alzheimer's disease patients. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating and preventing Alzheimer's disease and related neurodegenerative disorders using the SLC39A11 gene and its corresponding gene products. Screening methods for modulating agents of neurodegenerative diseases are also disclosed. | 10-08-2009 |
| 20090255004 | G-Protein Coupled Receptor and Uses Therefor - The present invention is based on the identification of a G-protein coupled receptor (GPCR) that is expressed predominantly in the brain and placenta and nucleic acid molecules that encoded the GPCR, which is referred to herein as the hCAR protein and hCAR gene respectively (for human Constitutively Active Receptor). Based on this identification, the present invention provides: (1) isolated hCAR protein; (2) isolated nucleic acid molecules that encode an hCAR protein; (3) antibodies that selectively bind to the hCAR protein; (4) methods of isolating allelic variants of the hCAR protein and gene; (5) methods of identifying cells and tissues that express the hCAR protein/gene; (6) methods of identifying agents and cellular compounds that bind to the hCAR protein; (7) methods of identifying agents that modulate the expression of the hCAR gene; and (8) methods of modulating the activity of the hCAR protein in a cell or organism. | 10-08-2009 |
| 20090265798 | Desaturase genes and uses thereof - The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 5 (i.e., “Δ5-desaturase”) and at carbon 6 (i.e., “Δ6-desaturase”) and to uses thereof. In particular, Δ5-desaturase may be utilized, for example, in the conversion of dihomo-γ-linolenic acid (DGLA) to arachidonic acid (AA) and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA). Delta-6 desaturase may be used, for example, in the conversion of linoleic (LA) to γ-linolenic acid (GLA). AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics. | 10-22-2009 |
| 20090307790 | ISOLATION OF THE T-COMPLEX DISTORTERS AND APPLICATIONS THEREOF - The present invention relates to a method for producing a transgenic non human male animal, preferably a mammal, fish, bird or insect, wherein the transgene(s) confer(s) a change in the transmission ratio of (a) genetic trait(s) to the offspring of said non human male animal, preferably mammal, fish, bird or insect to a non-Mendelian ratio, said method comprising introducing (a) a first nucleic acid molecule encoding an expression product with a Responder function into a chromosome of a non-human germ cell, (fertilized) egg cell, embryonic cell or a cell derived therefrom, of the same species as the transgenic male to be prepared, said chromosome containing or conferring said genetic trait(s), thereby linking on said chromosome said Responder function to the genetic trait(s); and (b) at least one second nucleic acid molecule encoding an expression product with a Distorter function into (a) chromosome(s) of a non-human germ cell, (fertilized) egg cell, embryonic cell or a cell derived therefrom, of the same species as the transgenic male to be prepared, wherein said expression product with a Distorter function is a factor involved in G protein signaling, wherein said first nucleic acid molecule encoding an expression product with Responder function and said at least one second nucleic acid molecule encoding an expression product with a Distorter function are introduced into the same or different chromosomes. | 12-10-2009 |
| 20090307791 | CALCIUM-ACTIVATED CHLORIDE CHANNEL AND METHODS OF USE THEREOF - The present invention provides a cloned, isolated calcium-activated chloride channel, and a polynucleotide comprising a nucleotide sequence encoding the channel. The present invention further provides a genetically modified cell comprising a subject polynucleotide, and use of the cells to identify agents that modulate calcium-activated chloride channel activity. The present invention further provides genetically modified cells and non-human animals that do not express a subject calcium-activated chloride channel. | 12-10-2009 |
| 20100077495 | COMPOSITIONS AND METHODS FOR THE EXPRESSION OF NUCLEIC ACIDS - Compositions and methods are provided herein for the expression of nucleic acids. Compositions and methods are also provided herein for inducible expression of nucleic acids in transgenic cells and animals using transposon-based nucleic acid constructs. Compositions and methods are also provided herein for modulation of endogenous gene expression. | 03-25-2010 |
| 20100100979 | BIOMARKER SPECIFIC FOR CANCER - It is an object of the present invention to provide diagnostic reagents, pharmaceuticals and the like for particular diseases, and providing means that are useful in developing such reagents, pharmaceuticals and the like. The present invention provides a novel polypeptide and a specific partial peptide thereof, as well as a novel polynucleotide and a specific partial nucleotide thereof, that can be used as cancer-specific biomarkers; an expression vector for such a polynucleotide and a specific partial peptide thereof; a transformant incorporating such an expression vector; an antisense molecule, RNAi-inducing nucleic acid (e.g., siRNA), aptamer, or antibody for a cancer-specific biomarker, and a composition comprising the same; a mammalian cell or non-human mammal wherein the expression or a function of a cancer-specific biomarker is regulated; a measuring means (e.g., primer set, nucleic acid probe, antibody, aptamer) for a cancer-specific biomarker, and a reagent comprising them and the like. | 04-22-2010 |
| 20100107264 | DEVELOPMENT OF INFLUENZA A ANTIVIRALS - The present invention includes compositions, methods and systems to isolate and characterize novel antiviral agents by contacting the antiviral agent with the F2F3 zinc fingers of a CPSF30 protein and an Influenza A NS1A protein; and determining whether the binding between the CPSF30 protein and the Influenza A NS1A protein is reduced. | 04-29-2010 |
| 20100122362 | CELLS EXPRESSING ALPHA-SYNUCLEIN AND USES THEREFOR - Disclosed are mammalian neuronal cells expressing alpha synuclein as well as methods of screening to identify compounds that decrease toxicity induced by alpha synuclein expression. Compounds identified by such screens can be used to treat or prevent synucleinopathies such as Parkinson's disease, familial Parkinson's disease, Lewy body disease, the Lewy body variant of Alzheimer's disease, dementia with Lewy bodies, multiple system atrophy, or the Parkinsonism-dementia complex of Guam. | 05-13-2010 |
| 20100122363 | Certain human genomic DNA associated with total red-green colorblindness - Disclosed is human genomic DNA having the following STR marker profile: | 05-13-2010 |
| 20100169994 | ANIMAL MODEL - The invention relates to the use of a NK1−/− animal as a model for attention deficit hyperactivity disorder and related conditions, to markers for those conditions and to methods of treating such conditions. | 07-01-2010 |
| 20100192240 | REGULATION OF EXPRESSION OF PI3KBETA PROTEIN IN TUMORS - The present invention concerns the use of PI3Kβ protein and/or encoding gene for the screening for substances useful in the treatment of cancers, preferably breast cancers. The present invention also concerns a method for the diagnosis of malignant cell growth comprising the measuring the expression of PI3Kβ gene. The invention concerns also non-human transgenic animals as model study for human pathologies, preferably breast cancer, being transgenic for having altered PI3Kβ and Neu-T expression. | 07-29-2010 |
| 20100199366 | Gene therapy using transposon-based vectors - Methods and compositions are presented for the administration of transposon based vectors to an animal or human to provide gene therapy to the animal or human. | 08-05-2010 |
| 20100212035 | Compositions and Methods for Producing Transgenic Mammals Having Recombinant Immunoglobulin Loci - The invention provides methods for the production of transgenic animals comprising a recombinant Ig locus, as well as transgenic antibodies derived therefrom. The methods involve meganuclease cleavage-stimulated homologous recombination in mammalian embryos. | 08-19-2010 |
| 20100218264 | Genome editing in rats using zinc-finger nucleases - Disclosed herein are methods and compositions for genome editing of one or more loci in a rat, using fusion proteins comprising a zinc-finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins. | 08-26-2010 |
| 20100223684 | HUMANIN RECEPTOR OR HUMANIN-LIKE POLYPEPTIDE RECEPTOR - One aspect of the present invention is directed to search receptors based on the information of HN signaling pathways in order to find Humanin receptor or Humanin-like polypeptide receptor (HNR), and to reveal a mechanism of promoting or suppressing the intracellular signal transduction for neuroprotecting activity of HN and identify a compound involved in the mechanism. The aspect of the invention is directed to a method for screening of HNR agonist and HNR antagonist, to utilize the screened compound in development of a drug for the treatment of neurodegenerative disease, and to provide an assay system of AD neuronal cell death, and to provide methods for the compulsory expression of HNR gene or knocking-out of intracellular genes. | 09-02-2010 |
| 20100223685 | IL-21 RECEPTOR KNOCKOUT ANIMAL AND METHODS OF USE THEREOF - A transgenic non-human mammal with a disruption in its IL-21 receptor gene is provided, along with methods of using the transgenic non-human mammal. | 09-02-2010 |
| 20100229253 | CHARACTERIZATION OF THE I-SPOMI ENDONUCLEASE FROM FISSION YEAST - Isolated DNAs encoding the enzyme I-Spoml and its recognition and cutting site are provided. The DNA sequences can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes. | 09-09-2010 |
| 20100235935 | PLASMA ANTI-DIABETIC NUCB2 PEPTIDE (PLADIN) AND USES THEREOF - The present invention provides pladin (plasma anti-diabetic nucb2 peptide) polypeptide and functional equivalent thereof that are useful for treating diabetes. The present invention provides a method of treating diabetes by administering to a subject nesfatin-1, pladin, or a functional equivalent thereof. The present invention also provides a method of treating diabetes by administering to subject plasmin inhibitors. | 09-16-2010 |
| 20100242125 | METHODS FOR CORRECTING MITOTIC SPINDLE DEFECTS AND OPTIMIZING PREIMPLANTATION EMBRYONIC DEVELOPMENTAL RATES ASSOCIATED WITH SOMATIC CELL NUCLEAR TRANSFER IN ANIMALS - The present invention is directed to various methodologies to make NT a practical procedure for animals, specifically, primates including human and non-human primates. Furthermore, the methods and molecular components provided by the present invention provide a practical means for producing embryos with desired characteristics. In a specific embodiment, the methodology of the present invention comprises introducing nuclei having desired characteristics along with one or more molecular components into an enucleated egg, thus creating a nuclear transfer construct, culturing the egg to produce a viable embryo, transferring the embryo to the oviducts of a female, and producing a cloned animal. | 09-23-2010 |
| 20100263066 | INERT DNA SEQUENCES FOR EFFICIENT VIRAL PACKAGING AND METHODS OF USE - The instant invention provides an inert DNA sequence having a length of between about 0.5 kb and about 5 kb, wherein said isolated inert DNA sequence does not contain an open reading frame and which is suitable for efficient packaging of expression cassettes comprising a nucleic sequence encoding a therapeutic agent into viral vectors, as well as methods of selecting such inert DNA sequences. The invention also provides DNA constructs and medical composition comprising such inert DNA sequences, and kits and medical systems for delivering such DNA constructs and/or compositions. | 10-14-2010 |
| 20100287635 | Cloned Canines and Method for Producing Thereof - Disclosed herein are a cloned canine and a production method thereof. The method comprises the steps of enucleating the oocyte of a canine to prepare an enucleated recipient oocyte, conducting nuclear transfer into the enucleated oocyte using a canine somatic cell as a nuclear donor cell under optimized conditions so as to prepare a nuclear transfer embryo, and transferring the nuclear transfer embryo into the oviduct of a surrogate mother. The present invention provides a method for producing cloned canines and thus, can contribute to the development of studies in veterinary medicine, anthropology and medical science such as the propagation of superior canines, the conservation of rare or nearly extinct canines, xenotransplantation and disease animal models. | 11-11-2010 |
| 20100319078 | Stem Cells Modified to Facilitate Threonine Catabolism - A mammalian cell comprising a recombinant, functional L-threonine 3-dehydrogenase (EC 1.1.1.103; TDH) gene, methods of making, and methods of use. | 12-16-2010 |
| 20100325746 | Methods and sequences to suppress primate huntington gene expression in vivo - Disclosed herein are sequences, molecules and methods used to suppress the expression of HD genes encoding for huntingtin protein in primates including | 12-23-2010 |
| 20110010785 | PRODUCTS AND THEIR USE FOR THE DIAGNOSIS, PREVENTION AND/OR CARE OF HUMAN AND/OR ANIMAL PATHOLOGIES CHARACTERISED BY THE ANOMALOUS DEPOSITION OF B-AMYLOID AND/OR AMYLOID-LIKE SUBSTANCE IN HUMAN AND/OR ANIMAL ORGANS AND TISSUES, AND SCREENING METHOD FOR DETERMINING THE RISK OF SUCH PATHOLOGIES - The patent refers to a screening method carried out on biological material isolated from human and/or animal organisms for determining the risk of human and/or animal pathologies expressing an anomalous deposition of β-amyloid and/or amyloid-like substance in human and/or animal organs and tissues, based on the investigation of the punctiform mutation Ala>Val in position 2 of the β-protein (corresponding to the Ala673Val mutation precursor of the β-protein containing 770 amino acids) in homozygosis or in heterozygosis. The patent provides for the possibility of: ( | 01-13-2011 |
| 20110016544 | Methods and compositions for detecting and treating retinal diseases based on metargidin (ADAM-15) - The invention discloses multiple genes related to age-related macular degeneration (AMD) and/or phagocytosis by RPE cells of the eye, and methods and compositions for detecting and treating AMD and other retinal degenerative conditions based on these phagocytosis-related and/or AMD-related genes. Also provided are animal models useful for testing therapeutic compounds and treatment protocols for AMD, and gene arrays including polymorphic variants of phagocytosis-related and/or AMD-related genes, useful for genetic screening of nucleic acid samples from subjects to obtain profiles of polymorphic variant sequences in a plurality of genes associated with AMD. | 01-20-2011 |
| 20110023156 | FELINE GENOME EDITING WITH ZINC FINGER NUCLEASES - The present invention provides a genetically modified feline or cell comprising at least one edited chromosomal sequence. In particular, the chromosomal sequence is edited using a zinc finger nuclease-mediated editing process. The disclosure also provides zinc finger nucleases that target specific chromosomal sequences in the feline genome. | 01-27-2011 |
| 20110023157 | EQUINE GENOME EDITING WITH ZINC FINGER NUCLEASES - The present invention provides a genetically modified equine or cell comprising at least one edited chromosomal sequence. In particular, the chromosomal sequence is edited using a zinc finger nuclease-mediated editing process. The disclosure also provides zinc finger nucleases that target specific chromosomal sequences in the equine genome. | 01-27-2011 |
| 20110030076 | Methods and compositions for targeted cleavage and recombination - Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins. | 02-03-2011 |
| 20110030077 | METHODS OF MODULATING THE ORGANIC SOLUTE AND STEROID TRANSPORTER (OSTalpha-OSTbeta) ACTIVITY AND TREATING ASSOCIATED CONDITIONS - The present invention is directed to methods of modulating bile acid and lipid transport via the organic solute and steroid transporter Ostα-Ostβ. The present invention is further directed to methods of treating a patient having dyslipidemia or a condition associated with altered bile acid homeostasis. Therapeutic agents and pharmaceutical compositions that modulate Ostα-Ostβ heteromeric complex formation and/or transport activity are also disclosed. | 02-03-2011 |
| 20110035819 | CODON OPTIMIZED CFTR - A synthetic hCFTR DNA sequence has been developed that produces remarkably high levels of hCFTR mRNA and protein in dosed murine lungs and human cells in culture compared to the natural hCFTR cDNA. This synthetic DNA addresses problems inherent in some natural cDNAs, such as premature transcriptional truncation sites introduced during cDNA synthesis. Introns are initially present in mRNA until the mRNA is processed. cDNA made from processed mRNA is devoid of introns. Thus DNA sequences (exon junctions) are present in a cDNA molecule which are not present in cells in nature. These exon junctions may affect transcription. Methods for improving expression of CFTR are based on sequence changes in cDNA molecules. The improvement methods may be applied to other cDNA molecules which are refractory to in vivo expression efforts. Compositions embodying the sequence changes increase the production of both transgenic mRNA and protein from cDNA molecules. | 02-10-2011 |
| 20110072527 | I-CREI MEGANUCLEASE VARIANTS WITH MODIFIED SPECIFICITY, METHOD OF PREPARATION AND USES THEREOF - Method of preparing I-CreI meganuclease variants having a modified cleavage specificity, variants obtainable by said method and their applications either for cleaving new DNA target or for genetic engineering and genome engineering for non-therapeutic purposes. Nucleic acids encoding said variants, expression cassettes comprising said nucleic acids, vectors comprising said expression cassettes, cells or organisms, plants or animals except humans, transformed by said vectors. | 03-24-2011 |
| 20110088106 | COMPOSITIONS AND METHODS FOR MEDIATING CELL CYCLE PROGRESSION - Hypercellular nonhuman organisms have functionally inactivated expression of a cyclin inhibitor gene, especially p27. The growth rate of nonhuman organisms are increased such that a desired size is attained more quickly than as compared to nonvariant organisms. Inhibitors of the p27 cyclin dependent kinase inhibitor protein or sequences encoding the protein modulate vertebrate cell cycle progression and increase the proportion of dividing cells to non-dividing cells in a population of treated cells. As the proportion of dividing cells increases, the cell population, e.g., hematopoietic progenitor (stem) cells, is more efficiently used for gene therapy applications. Transgenic animals and plants, and knockout alleles are provided. | 04-14-2011 |
| 20110093965 | PHOSPHOLIPASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - The invention provides novel polypeptides having phospholipase activity, including, e.g., phospholipase A, B, C and D activity, patatin activity, phosphatidic acid phosphatases (PAP) and/or lipid acyl hydrolase (LAH) activity, nucleic acids encoding them and antibodies that bind to them. Industrial methods, e.g., oil degumming, and products comprising use of these phospholipases are also provided. | 04-21-2011 |
| 20110113498 | SIRT1 POLYMORPHIC VARIANTS AND METHODS OF USE THEREOF - Provided herein are Sirt1 polymorphic variants having a substitution at amino acid residue 107 or nucleotide 373. In certain embodiments, the Sirt1 polypeptide variants have a L107P substitution and the nucleic acid variants have a T373C substitution. Genetic and/or biochemical testing may be performed to identify whether a patient carries one of the disclosed polymorphic variants. Based on the polymorphic variant the patient carries, a medical practitioner may administer an appropriate therapy, such as a sirtuin activator. | 05-12-2011 |
| 20110145941 | ANTIBODIES AND DERIVATIVES THEREOF - An anti-TrkA antibody is provided that comprises: | 06-16-2011 |
| 20110154520 | Vitamin K Epoxide Recycling Polypeptide VKORC1, a Therapeutic Target of Coumarin and Their Derivatives - The invention relates to a novel polypeptide vitamin K epoxide recycling polypeptide (VKORC1) as a target for coumarin and its derivatives. The invention further provides methods for identifying coumarin derivatives, and also claims VKORC1 polypeptides and VKORC1 nucleic acids containing a sequence abnormality associated with a VKORC1 associated deficiency such as warfarin resistance, wherein the VKORC1 polypeptides and VKORC1 nucleic acids can be used for diagnosing these deficiencies. Moreover, the invention relates to methods for identifying coumarin derivatives usable in pest control of rodents. | 06-23-2011 |
| 20110162096 | Gene Therapy Using Transposon-Based Vectors - Methods and compositions are presented for the administration of transposon-based vectors to an animal or human to provide gene therapy to the animal or human | 06-30-2011 |
| 20110179508 | ENTEROVIRUS TYPE 71 PROTEIN AND METHOD FOR PRODUCTION - The invention provides a new type of a capsid protein VP1 of human enterovirus 71, named as MEL701-VP1 and functional/structural variants thereof, which is used for protection against enterovirus. The transgenic animal producing the protein, the composition comprising the protein and the method for production thereof are also provided. | 07-21-2011 |
| 20110191874 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING CELL DEATH BY A TRANSLATION REGULATED GENE EXPRESSION SYSTEM - The technology relates to a nucleic acid expression cassette comprising a TR element encoding an mRNA molecule that is translated in stressed and/or dying cells, and a nucleotide sequence operably linked to the TR element, that is a first open reading frame (ORF) sequence and encodes a polypeptide or a fragment thereof and is co-translated with the TR element. The technology further relates to mammalian cells and a transgenic animal comprising such expression cassette. Further included are kits comprising the expression cassette, and methods for determining toxicity, and killing a target cell | 08-04-2011 |
| 20110247089 | Organisms homozygous for targeted modification - Disclosed herein are homozygously modified organisms and methods of making and using these organisms. | 10-06-2011 |
| 20110258715 | ORGAN REGENERATION METHOD UTILIZING iPS CELL AND BLASTOCYST COMPLEMENTATION - It is revealed that an organ such as pancreas can be regenerated by utilizing a fact that the deficiency of an organ is complemented by injecting an induced pluripotent stem cell (iPS cell) into a developed blastocyst in a blastocyst complementation method. Thus, the present invention has solved the above-described object. This provides a method for producing a target organ, using an iPS cell, in a living body of a non-human mammal having an abnormality associated with a lack of development of the target organ in a development stage, the target organ produced being derived from a different individual mammal that is an individual different from the non-human mammal. | 10-20-2011 |
| 20110265197 | Signatures and PCDeterminants Associated with Prostate Cancer and Methods of Use Thereof - The present invention provides methods of detecting cancer using biomarkers. | 10-27-2011 |
| 20110283374 | METHOD FOR PRODUCING HETEROGENOUS EMBRYONIC CHIMERIC ANIMAL USING A STEM CELL - A heterologous chimeric animal can be produced by a method comprising the steps of: (A) injecting a stem cell into a blastocyst cavity in a blastocyst stage of an animal heterologous to that of the stem cell, or mixing the stem cell with a divided fertilized egg of the animal heterologous to that of the stem cell; and (B) growing a cell mass including the stem cell prepared in the step (A) into a chimeric animal between a species of the stem cell and a species of the heterologous animal. | 11-17-2011 |
| 20120030782 | Compositions and Methods for Generating Transgenic Animals - The present invention provides methods of altering gene expression of embryos to provide compositions and methods for efficient generation of transgenic animals. In particular, the present invention provides compositions and methods for generating germline transgenic animals by direct injection of nucleic acid molecules into animals. | 02-02-2012 |
| 20120073003 | APOBEC3 MEDIATED DNA EDITING - The present invention relates to methods and compositions for preventing the occurance or progression of a cancer or pre-cancerous condition associated with expression, or over-expression of human cytidine deaminases of the APOBEC3 family. The invention also relates to drug screening assays designed to identify compounds that regulate the activity, or level of expression, of hA3A, hA3C and hA3H. The invention further relates to transgenic mice, as well as cells derived from said mice, that have been genetically engineered to express, or over-express hA3A, hA3C and/or hA3H. Such mice may be utilized to screen for, or identify, compounds that modulate the activity, or expression, of the human cytidine deaminases. The present invention also provides topical compositions such as cosmetic lotion, crème, or sunscreen for use on the skin, which comprise one or more inhibitors of human cytidine deaminase activity. The present invention relates to a double stranded DNA obtained following opening up of its duplex structure, said DNA being edited with cellular protein normally or abnormally expressed in the nucleus of an eukaryotic cell. The mono stranded DNA derived from the said double stranded DNA is a part of the present invention. | 03-22-2012 |
| 20120084871 | NPC1L1 ORTHOLOGUES - The present invention provides, in part, NPC1L1 from various species. Methods of using the NPC1L1 polypeptides and polynucleotide set forth herein, e.g., in screening assays, are also set forth. | 04-05-2012 |
| 20120084872 | METHODS FOR PRODUCING MICRORNAS - The invention relates to recombinant vectors for inducible and/or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene. In certain embodiments, the invention relates to the use of Tet (tetracycline)-responsive RNA Polymerase II (Pol II) promoters (e.g., TetON or TetOFF) to direct inducible knockdown in certain cells of an integrated or an endogenous gene, such as p53. The invention also relates to a method for producing transgenic animals (e.g., mice) expressing inducible (such as tetracycline-regulated), reversible, and/or tissue-specific double-stranded RNA molecules that interfere with the expression of a target gene. | 04-05-2012 |
| 20120090043 | TARGETS FOR RETROVIRUS ASSOCIATED DISEASES - The invention concerns an isolated complex comprising an HIV or HTLV protein and a human protein. Corresponding nucleic acids, vectors, host cells, host organisms, compositions, kits, medical uses, diagnostic uses, and methods of screening agents are also contemplated. Disclosed are 212 interactions between 19 retroviral proteins and 131 human proteins. | 04-12-2012 |
| 20120110686 | Cand45 tRNA-Derived Expression System for Gene Modulation - The present invention relates to systems and methods for modulating gene expression and applications thereof. Provided is a novel expression system to generate RNaseZ and RNA polymerase III dependent RNAs to regulate genes and control the timing and the location of the regulation by supplying synthetic or expressed oligonucleotide antisense to a small RNA. | 05-03-2012 |
| 20120117674 | METHOD FOR GENERATING REPLICATION DEFECTIVE VIRAL VECTORS THAT ARE HELPER FREE - Sequences are provided that are capable of directing circular adeno-associated virus replication, useful in vectors for providing therapeutic agents to a subject in need thereof. The vectors of the invention are particularly useful in the treatment of acute medical conditions requiring rapid gene expression. Further provided are methods for producing packaged defective viral vectors. | 05-10-2012 |
| 20120124685 | COMPOSITIONS AND METHODS FOR GENE EXPRESSION AND CHROMATIN PROFILING OF INDIVIDUAL CELL TYPES WITHIN A TISSUE - The present invention provides compositions, methods, and kits for generating and isolating tagged nuclei of specific cell types with a high yield and purity. The compositions, methods, and kits provided herein comprise expressing in a cell a nuclear envelope tagging fusion polypeptide comprising a nuclear envelope targeting domain and an affinity reagent binding region. In some embodiments, expression of the fusion polypeptide is under the control of a cell type-specific promoter. Some embodiments also comprise expressing in a cell a biotin ligase, wherein the affinity reagent binding region comprises a biotin ligase accepting site, and wherein at least one of the nuclear envelope tagging fusion polypeptide and the biotin ligase is expressed under the control of a cell type-specific promoter. | 05-17-2012 |
| 20120151613 | MUTANTS OF ACTIVATION-INDUCED CYTIDINE DEAMINASE (AID) AND METHODS OF USE - The invention provides functional mutants of activation-induced cytidine deaminase (AID) protein that have increased activity as compared to a wild-type AID protein. The invention also provides nucleic acids encoding the functional AID mutants, and vectors and cells comprising the nucleic acids. The invention further provides methods of using the functional mutant AID proteins. | 06-14-2012 |
| 20120159660 | DESATURASES AND METHODS OF USING THEM FOR SYNTHESIS OF POLYUNSATURATED FATTY ACIDS - The amino acid and nucleic acid sequences of a Δ | 06-21-2012 |
| 20120167238 | UNIVERSAL PEPTIDE TAGS FOR TRANSGENE POLYPEPTIDE ANALYSIS BY MASS SPECTROMETRY - Compositions and methods that allow for the rapid detection and accurate quantification of any polypeptides of interest are provided. Compositions include isolated polypeptides comprising at least one universal peptide tag, as well as isolated polynucleotides encoding such polypeptides. The universal peptide tags can be quantified by methods including, but not limited to, mass spectrometry, and can act as surrogates for determining the concentration of the polypeptides comprising the universal peptide tags. Methods provide for the detection and/or quantification of any polypeptides of interest that comprise at least one universal peptide tag, including methods using mass spectroscopy techniques. Methods are also provided for producing hosts, or cells or parts thereof, that comprise polypeptides comprising at least one universal peptide tag. Hosts, or cells, or parts thereof, include mammalian, bacterial, insect, yeast, viral or plant. | 06-28-2012 |
| 20120180150 | INOSITOL 1,4,5-TRIPHOSPHATE RECEPTOR-BINDING PROTEIN AND ITS NON-HUMAN TRANSGENIC MAMMALIAN ANIMALS - The instant invention provides an inositol 1,4,5-triphaosphate receptor (IP3R)-binding protein and its transgenic non-human mammalian animal. | 07-12-2012 |
| 20120192298 | METHOD FOR GENOME EDITING - The present invention encompasses a method for creating an animal or cell with at least one chromosomal edit. In particular, the invention relates to the use of targeted zinc finger nucleases to edit chromosomal sequences. The invention further encompasses an animal or a cell created by a method of the invention. | 07-26-2012 |
| 20120240247 | JNK3 MODULATORS AND METHODS OF USE - The c-Jun NH | 09-20-2012 |
| 20120255045 | INDUCIBLE SMALL RNA EXPRESSION CONSTRUCTS FOR TARGETED GENE SILENCING - The invention relates to vectors for the inducible expression of RNA molecules in eukaryotic, particularly mam | 10-04-2012 |
| 20120255046 | IN VIVO TRANSDUCTION WITH A CHIMERIC AAV CAPSID PROTEIN - Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating a library of recombinant adeno-associated viral capsid proteins are also provided. | 10-04-2012 |
| 20120272349 | METHOD FOR CONSTRUCTING CHIMERIC RAT USING RAT EMBRYONIC STEM CELLS - The present invention provides a preparation method of a chimeric embryo and a chimeric rat, which is characterized by contacting a rat pluripotent stem cell and a host embryo in the presence of an ES cell differentiation inhibitor. The method includes (a) a step for contacting a fertilized host embryo collected from a female rat and a rat pluripotent stem cell in the presence of an ES cell differentiation suppressant, and (b) a step for culturing the host embryo in contact with the rat pluripotent stem cell to form a chimeric embryo. | 10-25-2012 |
| 20120331575 | TRANSGENIC NON-HUMAN ANIMALS - The invention provides a non-human transgenic animal comprising a transgene encoding angiogenin and food products comprising or obtained from the non-human transgenic animal and uses thereof. | 12-27-2012 |
| 20130042334 | Capping-Prone RNA Polymerase Enzymes and Their Applications - The invention provides a chimeric enzyme comprising at least one catalytic domain of a RNA triphosphatase, at least one catalytic domain of a guanylyltransferase, at least one catalytic domain of a N | 02-14-2013 |
| 20130067609 | Mammalian Genes Involved in Tularemia and Other Infections - The present invention relates to nucleic acid sequences and cellular proteins encoded by these sequences that are involved in infection or are otherwise associated with the life cycle of one or more pathogens. | 03-14-2013 |
| 20130117870 | GENETICALLY MODIFIED ANIMALS AND METHODS FOR MAKING THE SAME - Compositions and methods for use of TALENs to make genetically modified livestock or other animals are set forth. Some of the embodiments of the invention provide for making an founder animal that is completely free of all unplanned genetic modifications. Some embodiments are directed to removing genetic faults in established breeds without making other alterations to the genome. Other embodiments are directed to particular tools or processes such as a TALENs with a preferred truncation. | 05-09-2013 |
| 20130174289 | Na+/Mg2+ Exchanger - The invention relates to methods to identify new SLC41A1 functions at the cell, tissue, organ and organism level. In part, it is related to methods useful in (a) identifying molecules that bind SLC41A1 polypeptides, which (b) modulate SLC41A1 related Na | 07-04-2013 |
| 20130179999 | NOVEL STRUCTURALLY DESIGNED shRNAs - Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules. | 07-11-2013 |
| 20130185818 | METHOD TO TRIGGER RNA INTERFERENCE - A method to generate siRNAs in vivo is described, as are constructs and compositions useful in the method. The method does not depend on the use of DNA or synthetic constructs that contain inverted duplications or dual promoters so as to form perfect or largely double-stranded RNA. Rather, the method depends on constructs that yield single-stranded RNA transcripts, and exploits endogenous or in vivo-produced miRNAs or siRNAs to initiate production of siRNAs. The miRNAs or siRNAs guide cleavage of the transcript and set the register for production of siRNAs (usually 21 nucleotides in length) encoded adjacent to the initiation cleavage site within the construct. The method results in specific formation of siRNAs of predictable size and register (phase) relative to the initiation cleavage site. The method can be used to produce specific siRNAs in vivo for inactivation or suppression of one or more target genes or other entities, such as pathogens. | 07-18-2013 |
| 20130198878 | ORGANISMS HOMOZYGOUS FOR TARGETED MODIFICATION - Disclosed herein are homozygously modified organisms and methods of making and using these organisms. | 08-01-2013 |
| 20130219532 | PEPTIDES WITH ANTIFUNGAL ACTIVITIES - The present invention relates to antifungal and/or antibacterial peptides, especially antifungal peptides obtained from insect species, particularly lepidopterans. The present invention also provides methods of using these antifungal peptides to treat or prevent fungal growth for a variety of purposes, such as protecting plants from fungal infections; treating fungal infections of animals, especially humans; and prevention of food spoilage. | 08-22-2013 |
| 20130283404 | EPIGENETICS IN AUTOIMMUNITY - Provided herein are compositions and methods for the diagnosis, monitoring, treatment, and/or prevention of autoimmune disease (e.g., lupus) based on a causal connection with various epigenetic markers (e.g., chromosome demethylation, overexpression of lupus markers, nitration of PKCδ in response to oxidative stress, etc.). | 10-24-2013 |
| 20130326645 | METHODS AND COMPOSITIONS FOR NUCLEASE-MEDIATED TARGETED INTEGRATION OF TRANSGENES - Disclosed herein are methods and compositions for homology-independent targeted insertion of donor molecules into the genome of a cell. | 12-05-2013 |
| 20130326646 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING NEUROLOGICAL CONDITIONS - The present invention relates to the NIPA-1 proteins and nucleic acids encoding the NIPA-1 proteins. The present invention further provides assays for the detection of NIPA-1 polymorphisms and mutations associated with disease states, as well as methods of screening for ligands and modulators of NIPA-1 proteins. | 12-05-2013 |
| 20140013457 | Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification. | 01-09-2014 |
| 20140033336 | Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification. | 01-30-2014 |
| 20140041066 | PRODUCTION OF FMDV-RESISTANT LIVESTOCK BY ALLELE SUBSTITUTION - A genetically modified livestock animal comprising a genomic modification to an eIF4G gene. Cells, genes, and proteins encompassing a protease-resistant eIF4G protein or gene. | 02-06-2014 |
| 20140041067 | ANTIBODIES, VARIABLE DOMAINS & CHAINS TAILORED FOR HUMAN USE - The invention relates to the provision of antibody therapeutics and prophylactics that are tailored specifically for human use. The present invention provides libraries, vertebrates and cells, such as transgenic mice or rats or transgenic mouse or rat cells. Furthermore, the invention relates to methods of using the vertebrates to isolate antibodies or nucleotide sequences encoding antibodies. Antibodies, heavy chains, polypeptides, nucleotide sequences, pharmaceutical compositions and uses are also provided by the invention. | 02-06-2014 |
| 20140053287 | Aldolases, Nucleic Acids Encoding Them and Methods for Making and Using Them - This invention relates to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In some embodiments, the invention is directed to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides in accordance with the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts. In some embodiments, the invention provides polypeptides and biosynthetic pathways that are useful in the production of R-2-hydroxy 2-(indol-3ylmethyl)-4-keto glutaric acid (R-MP) and certain stereoisomers of monatin, such as R,R and S,R monatin, and salts thereof, as well as certain stereoisomers of monatin derivatives, such as the R,R and S,R configurations, and salts thereof. | 02-20-2014 |
| 20140059709 | CONTROL OF URIC ACID HOMEOSTASIS - The invention relates to vectors and mammalian cells in a system useful for switching on or switching off gene expression in response to uric acid. In a particular embodiment the invention relates to a mammalian cell useful in detecting and/or degrading a harmful excess of uric acid comprising (a) a vector comprising a genetic code for the uricase sensor-regulator HucR from | 02-27-2014 |
| 20140075585 | Tetraspanin CD82 as a Diagnostic and/or Therapeutic Module for Xenograft Recognition and/or Rejection - The present invention relates to CD82 polypeptides of the mammalian tetraspanin CD82 protein family for use in the diagnosis, prevention and/or treatment of xenograft recognition and/or rejection. The present invention furthermore relates to CD82 knockout and transgenic animals and their cells, tissues and organs. The present invention furthermore relates to antibodies against a CD82 polypeptide, pharmaceutical compositions comprising at least one inhibitor of a CD82 polypeptide or comprising cells, tissues and organs of animals in which the CD82 level, expression and/or activity is modified, and their use in the diagnosis, prevention and/or treatment of xenograft recognition and/or rejection. The present invention furthermore relates to methods of diagnosing xenograft recognition and/or rejection and methods for the prevention and/or treatment of xenograft recognition and/or rejection as well as methods of xenotransplantation. | 03-13-2014 |
| 20140109247 | RAT EMBRYONIC STEM CELL - The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like. | 04-17-2014 |
| 20140150125 | ANIMAL MODELS AND THERAPEUTIC MOLECULES - The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods. | 05-29-2014 |
| 20140165222 | HIGH AFFINITY SUMO TRAPS - The potential use of these “SUMO receptors” to isolate SUMOylated targets has been considered using the SIM sequences of the SUMO-dependent ubiquitin-protein ligase RNF4. RFN4 contains 4 SIM sequences known to interact with SUMOylated proteins. The capacity of the SIM2 and SIM3 of RNF4 to purify SUMOylated proteins was increased when in the present invention it was disposed in tandem up to 4 SIM sequences. In a preferred embodiment to increase flexibility and functionality of this SUMO-trap, we have changed the natural linkers resulting in a broader capture of SUMOylated proteins. This Tandem SUMO Interacting Motifs (TSIMs) or SUMO-Binding Entities (SUBEs) system disclosed in the present invention is useful to capture polySUMOylated proteins from cell extracts. Therefore, in another embodiment of the present invention, TSIMs or SUBEs can be used for the identification SUMO substrates and the study of SUMO-regulated processes. | 06-12-2014 |
| 20140201855 | MUTANT LUCIFERASES - Described are mutant luciferases, nucleic acids that encode them, cells and animals expressing them, methods of use thereof, and kits. | 07-17-2014 |
| 20140201856 | ANIMAL MODELS AND THERAPEUTIC MOLECULES - The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods. | 07-17-2014 |
| 20140298502 | DESATURASES AND METHODS OF USING THEM FOR SYNTHESIS OF POLYUNSATURATED FATTY ACIDS - The amino acid and nucleic acid sequences of a Δ | 10-02-2014 |
| 20140310829 | MODIFIED PARVOVIRUS USEFUL FOR GENE SILENCING - Described are methods for efficiently down regulating the expression of a gene of interest in a cell by use of a modified rodent parvovirus that contains an expressible target specific nucleic acid, preferably an shRNA expression cassette. Also described are cells or organisms comprising said parvovirus. | 10-16-2014 |
| 20140338007 | METHOD AND MATERIALS FOR PRODUCING A GENETICALLY MODIFIED ANIMAL - Transgenic artiodactyls are described as well as methods of making and using such artiodactyls. | 11-13-2014 |
| 20150040252 | NOVEL BETA-ACTIN AND RPS21 PROMOTERS AND USES THEREOF - The invention relates to isolation of novel β-actin and ribosomal protein S21 (rpS21) promoters and uses thereof. In particular, this invention features nucleotide sequences for rodent β-actin promoters including, hamster, rat, and mouse, and hamster rpS21 promoter. | 02-05-2015 |
| 20150052626 | COMPOSITIONS AND METHODS FOR FLUORESCENT GENETIC BAR-CODING IN MAMMALIAN CELLS FOR ENHANCED MULTIPLEXING CAPABILITIES IN FLOW CYTOMETRY - The invention provides cells or populations of cells, including non-human animals or non-human mammals having these cells, where the cells or populations of cells are stably tagged, uniquely identified and genetically barcoded by one or more detectable, e.g., fluorescent, proteins; and methods of making and using them. In alternative embodiments, the invention provides methods for tagging, uniquely identifying or genetically barcoding a cell, a population of cells, or a culture of cells by stably transferring, transfecting, transducing, infecting or implanting one or more nucleic acids encoding readable or detectable, e.g., fluorescent, moieties into the cells. In alternative embodiments, the nucleic acids are stably inserted into the cells such that the readable or detectable, e.g., fluorescent, genetic barcoding becomes a stable, heritable characteristic of the cell. In alternative embodiments, the invention provides fluorescent barcoded multiplexed cell-based assays using several different fluorescent proteins. The multiplexing power of methods of the invention can be increased by combining both the number of distinct fluorescent proteins and the fluorescence intensity in each channel. | 02-19-2015 |
| 20150096066 | TARGET MOLECULES FOR TRANSCRIPTIONAL CONTROL SYSTEMS - The invention provides systems to control gene expression or activity using target molecules. | 04-02-2015 |
| 20150128300 | METHODS AND COMPOSITIONS FOR GENERATING CONDITIONAL KNOCK-OUT ALLELES - The disclosure provides methods and compositions for generating conditional knock-out alleles using donor constructs together with sequence-specific nucleases to generate conditional knock-out alleles. Specifically, the donor construct comprises a 5′ homology region, a 5′ recombinase recognition site, a donor sequence, a 3′ recombinase recognition site, and a 3′ homology region. Further disclosed are the donor sequences each comprises a target sequence having at least one neutral mutation. Different sequence-specific nucleases can be used with the donor constructs are further disclosed. | 05-07-2015 |
| 20160053274 | TARGETED GENOME ENGINEERING IN EUKARYOTES - Improved methods and means are provided to modify in a targeted manner the genome of a eukaryotic cell at a predefined site using a double stranded break inducing enzyme such as a TALEN and a donor molecule for repair of the double stranded break. | 02-25-2016 |
| 20160083738 | PRODUCTION OF BACTERIAL MICROCOMPARTMENTS IN EUKARYOTIC CELLS - The invention relates to eukaryotic organisms such as vascular plants that include recombinant microcompartments. | 03-24-2016 |
| 20160152994 | METHODS CONTROLLING GENE EXPRESSION | 06-02-2016 |
| 20160153004 | DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETING AND MODELING DISEASES AND DISORDERS OF POST MITOTIC CELLS | 06-02-2016 |
| 20160165861 | GENETICALLY MODIFIED CELLS, TISSUES, AND ORGANS FOR TREATING DISEASE | 06-16-2016 |
| 20160174533 | GENETICALLY MODIFIED RAT MODELS FOR DRUG METABOLISM | 06-23-2016 |
